JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kassis, A. I.
Right arrow Articles by Adelstein, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kassis, A. I.
Right arrow Articles by Adelstein, S. J.
Journal of Nuclear Medicine Vol. 46 No. 1 (Suppl) 4S-12S
© 2005 by Society of Nuclear Medicine

Radiobiologic Principles in Radionuclide Therapy

Amin I. Kassis, PhD; and S. James Adelstein, MD, PhD

Department of Radiology, Harvard Medical School, Boston, Massachusetts

Although the general radiobiologic principles underlying external beam therapy and radionuclide therapy are the same, there are significant differences in the radiobiologic effects observed in mammalian cells. External beam and brachytherapy emissions are composed of photons, whereas radiations of interest in radionuclide therapy are particulate. The special features that characterize the biologic effects consequent to the traversal of charged particles through mammalian cells are explored with respect to DNA lesions and cellular responses. Information about the ways in which these radionuclides are used to treat cancers in experimental models are highlighted.

Key Words: {alpha}-particle emitters • Auger-electron emitters • ß-particle emitters • radiobiology • radionuclide therapy




This article has been cited by other articles:


Home page
 JNMHome page
C. Champion, P. Zanotti-Fregonara, and E. Hindie
CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distribution S Values for 131I in Spheres of Various Sizes
J. Nucl. Med., January 1, 2008; 49(1): 151 - 157.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Sgouros, S. J. Knox, M. C. Joiner, W. F. Morgan, and A. I. Kassis
MIRD Continuing Education: Bystander and Low Dose-Rate Effects: Are These Relevant to Radionuclide Therapy?
J. Nucl. Med., October 1, 2007; 48(10): 1683 - 1691.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. N. Reske, S. Deisenhofer, G. Glatting, B. D. Zlatopolskiy, A. Morgenroth, A. T. J. Vogg, A. K. Buck, and C. Friesen
123I-ITdU-Mediated Nanoirradiation of DNA Efficiently Induces Cell Kill in HL60 Leukemia Cells and in Doxorubicin-, {beta}-, or {gamma}-Radiation-Resistant Cell Lines
J. Nucl. Med., June 1, 2007; 48(6): 1000 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli
Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Ferrari, M. Cremonesi, M. Bartolomei, L. Bodei, M. Chinol, M. Fiorenza, G. Tosi, and G. Paganelli
Dosimetric Model for Locoregional Treatments of Brain Tumors with 90Y-Conjugates: Clinical Application with 90Y-DOTATOC
J. Nucl. Med., January 1, 2006; 47(1): 105 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G A Kaltsas, D Papadogias, P Makras, and A B Grossman
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.